Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy

Valerie M. Carlberg, Olivia M.T. Davies, Heather A. Brandling-Bennett, Sarah E.S. Leary, Jennifer T. Huang, Carrie C. Coughlin, Deepti Gupta

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Cancer remains a leading cause of morbidity and mortality among children. Targeted therapies may improve survivorship; however, unique side-effect profiles have also emerged with these novel therapies. Changes in hair, skin, and nails—termed dermatologic adverse events (AEs)—are among the most common sequelae and may result in interruption or discontinuation of therapy. Though dermatologic AEs have been detailed in adults, these findings are not well described in the pediatric population. We reviewed the literature to characterize dermatologic AEs to anticancer targeted therapies available as of July 2020 and summarized the spectrum of clinical findings as well as treatment recommendations for children. Dermatologic AEs are among the most common AEs reported in pediatric patients receiving targeted therapy, but morphologic and histologic descriptions are often lacking in current publications. Pediatric dermatologists are uniquely poised to recognize specific morphology of dermatologic AEs and make recommendations for prevention and treatment that may improve quality of life and enable ongoing cancer therapy.

Original languageEnglish
Pages (from-to)18-30
Number of pages13
JournalPediatric Dermatology
Volume38
Issue number1
DOIs
StatePublished - Jan 1 2021
Externally publishedYes

Keywords

  • adverse reactions
  • cutaneous toxicity
  • oncodermatology
  • pediatric
  • targeted therapy

Fingerprint

Dive into the research topics of 'Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy'. Together they form a unique fingerprint.

Cite this